Bruk av medikamenter og senere sykelighet og dødelighet
The project will provide information on how medicines are used in the general population.
About the project
-
Project period: 01.02.2010 - 31.01.2027 (Active)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Vidar Hjellvik, Norwegian Institute of Public Health
-
Project Participants:
- Vidar Hjellvik, Physical Health and Ageing
- Zoltan Thinsz, Karolinska Institutet
- Peter Vestergaard, Aalborg University
- Morten Andersen, Karolinska Institutet
- Matti Siivola, University of Helsinki
- Mark C.H. De Groot, Utrecht University
- Marjanka K. Schmidt, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
- Jari Haukka, University of Helsinki
- Anna But, University of Helsinki
- Per Minor Magnus, Centre for Fertility and Health
- Tone Bjørge, Department of Global Public Health and Primary Care
- Sara Ghaderi, Department of Global Public Health and Primary Care
- Anders Engeland, Physical Health and Ageing
- Lars Jøran Kjerpeseth, Physical Health and Ageing
- Marte Handal, Public Health and Prevention
- Svetlana Ondrasova Skurtveit, Public Health and Prevention
- Ingeborg Hartz, Forskning og innovasjon
- Eva Skovlund, Department of Public Health and Nursing
- Jon Marius Grasto Wickmann, Health Studies
- Øystein Karlstad, Physical Health and Ageing
- Randi Marie Selmer, Physical Health and Ageing
- Kari Furu, Physical Health and Ageing
- Inger Johanne Landsjøåsen Bakken, Centre for Fertility and Health
- Helena Niemi Eide, Infection Control and Preparedness
- Mariam Anjum, Vestre Viken Hospital Trust
- Inger Kristine Holtermann Ariansen, Physical Health and Ageing
Summary
Clinical trials of drugs have restrictions that limit the knowledge of new drugs at the time of marketing: relatively few people in a limited period of time have been exposed to the drug. Signs of adverse reactions should therefore be evaluated after the drugs have been taken in normal use by the population using epidemiological studies in which systematic bias is attempted to be avoided. Knowledge of how drugs are used in the population is also important. The project will provide information on how medicines are used in the general population - and on effects and side effects - by linking the Norwegian Prescription Database with the Cause of Death Register, the Patient Register, the Cancer Registry, health surveys (three counties, 40-year surveys 1985-1999 and CONOR 1994-2003) and socioeconomic information from Statistics Norway. The following specific issues are included:
a) Use of the insulin analogue Lantus and cancer risk.
b) Medicine use and diagnoses for ADHD.
c) Use of psychiatric drugs among children and adolescents.
d) Medical prevention of stroke in atrial fibrillation.
e) Drug treatment before and after hospital admissions for asthma.
f) The connection between the use of sedative medicine, sleep medicine, cancer and mortality.
g) Prescription drug use among cancer survivors.
h) Prescription of drugs for and mortality of cardiovascular disease
i) Sleep problems, hypnosis and later ADHD.